bluebird up on first outcomes-based Medicaid agreement for sickle cell gene therapy

Crispr Therapeutics AG

11/03/2024 14:01

** Shares of gene therapy developer bluebird bio  BLUE.O 
rise 3.33% to $1.55
    ** BLUE says it has signed its first Medicaid outcomes-based
agreement with the state of Michigan for its sickle cell gene
therapy Lyfgenia
    ** bluebird is in ongoing discussions with more than 15
Medicaid agencies representing 80% of Medicaid-insured
individuals in the U.S.
    ** Company's outcomes-based contract offering for State
Medicaid Agencies was designed with input from government payers
to address the challenges they face in adapting to provide
access to one-time, transformative treatments
    ** bluebird's therapy Lyfgenia and Casgevy, developed by
partners Vertex Pharmaceuticals  VRTX.O  and CRISPR Therapeutics
 CRSP.BN , were approved by the U.S. FDA on Dec. 8, 2023
    ** BLUE down 69.8% in the last 12 months
    

 (Reporting by Christy Santhosh and Sriparna Roy)
 ((Christy.Santhosh@thomsonreuters.com))